Analogues of Pyridoxal Isonicotinoyl Hydrazone (PIH) as Potential Iron Chelators for the Treatment of Neoplasia
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Cancer cells have a high requirement for iron (Fe) as it plays a crucial role in a variety of metabolic processes including energy production and DNA synthesis. Studies in vitro and in vivo have demonstrated that the Fe chelator in current clinical use, desferrioxamine (DFO), can effectively inhibit the growth of some neoplasms, including leukemia and neuroblastoma. Unfortunately, DFO suffers from a number of serious disadvantages, including its high cost, the need for prolonged subcutaneous infusion (12-24 h/day, 5-6 nights/week), and its poor intestinal absorption precluding oral administration. Hence, the development of more effective Fe chelators is necessary. The Fe chelator, pyridoxal isonicotinoyl hydrazone (PIH), was initially identified as a ligand that showed high activity at mobilizing Fe from cells. More recently, a range of PIH analogues have been examined for their anti-proliferative effect, with several classes of these compounds showing high activity at inhibiting tumor growth in vitro. In fact, some of these hydrazones, particularly those derived from 2-hydroxy-1-naphthylaldehyde, showed comparable activity to the cytotoxic drugs cis-platin and bleomycin. In this review the role of Fe in cellular proliferation will be examined followed by a description of the most recent studies using the PIH analogues as effective anti-proliferative agents. Further studies in vivo with these Fe chelators are essential to determine their potential as chemotherapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene
Fleming, M. D., Trenor, C. C., Su, M. A., Foernzler, D., Beier, D. R., Dietrich, W. F., & Andrews, N. C. (1997) · Nature Genetics · doi:10.1038/ng0897-383 · Cited by 1,159
Iron withholding: a defense against infection and neoplasia
Weinberg, E. D. (1984) · Physiological Reviews · doi:10.1152/physrev.1984.64.1.65 · Cited by 881
Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., & Greaves, M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4515 · Cited by 685
Richardson, D. R., & Ponka, P. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90180-9 · Cited by 126
Self-citation
Cited by
The role of iron in cell cycle progression and the proliferation of neoplastic cells
Le, N. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00068-9 · Cited by 453
Richardson, D. R., & Ponka, P. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90180-9 · Cited by 126
Self-citationCell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents
Pahl, P. M. B., & Horwitz, L. D. (2005) · Cancer Investigation · doi:10.1080/07357900500359976 · Cited by 40
“Pyridoxal isonicotinoyl hydrazone (PIH) (Figure 1B) is a lipid soluble tridentate chelator with a high affinity for Fe3+.[79] PIH and several of its analogues are more effective than DFO at preventing cell growth.”
BackgroundTherapeutic Potential of Iron Chelators in Cancer Therapy
Richardson, D. R. (2002) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0593-8_12 · Cited by 40
Self-citation
Metadata
- Authors
- Richardson, D. R.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 1998-01
- Volume
- 31
- Issue
- 1-2
- Pages
- 47-60
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W1992367796
- Cited by
- 26
- References
- 4
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analogues of Pyridoxal Isonicotinoyl Hydrazone (PIH) as Potential Iron Chelators for the Treatment of Neoplasia. https://app.cochat.ai/papers/10.3109/10428199809057584
- The paper
- Richardson, D. R. (1998). Analogues of Pyridoxal Isonicotinoyl Hydrazone (PIH) as Potential Iron Chelators for the Treatment of Neoplasia. Leukemia & Lymphoma. https://doi.org/10.3109/10428199809057584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.